RNA-programmable endonuclease systems and uses thereof

US12203110B2 · kind B2 · utility

Assignees

• CRISPR THERAPEUTICS AG · CH
• BAYER HEALTHCARE LLC · DE

Inventors

• Andre COHNEN · Hasselsweiler, DE
• Moritz Schmidt · Cologne, DE
• Wayne Coco · Cologne, DE
• Michael Biag Gamalinda · Leverkusen, DE
• Ashish Gupta · Sunnyvale, US
• Christian Pitzler · Leverkusen, DE
• Florian Richter · Mannheim, DE
• Jan Tebbe · Cologne, DE
• Christopher Cheng · Cambridge, US
• Ryo Takeuchi · Cambridge, US
• Caroline Reiss · Cambridge, US

Key dates

• Filing date: Mar 19, 2019
• Grant date: Jan 21, 2025
• Expiry date: Mar 10, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2800/80
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.